Inventor · disambiguated record
Shane Olwill
Also filed as: OLWILL SHANE · OLWILL SHANE A
21 granted patents·12 pending applications·28 citations·filing 2006–2022
92Inventor score
Files withPIERIS PHARMACEUTICALS GMBH23FUSION ANTIBODIES LTD4CASWELL JILL1OLWILL SHANE1OLWILL SHANE A1
Top patents by PatentIndex Score
33 records- 0192US10526382B2Human neutrophil gelatinase-associated lipocalin (hNGAL) muteins capable of binding angiopoietin-2 (Ang-2) and methods of use thereofPIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Jan 7, 2020·6 cites·47 claims
- 0287US11773147B2Lipocalin muteins with binding affinity for LAG-3PIERIS PHARMACEUTICALS GMBH·Filed 2021·Granted Oct 3, 2023·1 cites·20 claims
- 0387US10526384B2Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereofPIERIS PHARMACEUTICALS GMBH·Filed 2013·Granted Jan 7, 2020·5 cites·16 claims
- 0485US11919931B2Anti-cancer fusion polypeptide capable of binding both CD137 and glypican-3 (GPC3)PIERIS PHARMACEUTICALS GMBH·Filed 2021·Granted Mar 5, 2024·1 cites·6 claims
- 0583US10501510B2Muteins of human tear lipocalin capable of binding lymphocyte-activation gene 3 (LAG-3) and methods of use thereofPIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Dec 10, 2019·4 cites·23 claims
- 0682US11261221B2Proteins specific for CD137PIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Mar 1, 2022·2 cites·12 claims
- 0780US10927156B2Human tear lipocalin muteins which specifically bind lymphocyte activation gene-3 (LAG3) and method of use thereof to stimulate an immune responsePIERIS PHARMACEUTICALS GMBH·Filed 2019·Granted Feb 23, 2021·1 cites·10 claims
- 0874US11168119B2Lipocalin muteins with binding affinity for LAG-3PIERIS PHARMACEUTICALS GMBH·Filed 2018·Granted Nov 9, 2021·1 cites·28 claims
- 0972US12195503B2Proteins specific for CD137PIERIS PHARMACEUTICALS GMBH·Filed 2022·Granted Jan 14, 2025·0 cites·17 claims
- 1071US10913778B2Anti-cancer fusion polypeptides, encoding nucleic acids and methods of using polypeptidesPIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Feb 9, 2021·1 cites·33 claims
- 1171US10865250B2Anti-cancer fusion polypeptidePIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Dec 15, 2020·1 cites·8 claims
- 1266US10927154B2Multi-specific polypeptide useful for localized tumor immunomodulationPIERIS PHARMACEUTICALS GMBH·Filed 2015·Granted Feb 23, 2021·1 cites·6 claims
- 1363US11034738B2Nucleic acid molecules encoding human neutrophil gelatinase-associated lipocalin (hNGAL) which bind angiopoietin-2 (Ang-2)PIERIS PHARMACEUTICALS GMBH·Filed 2019·Granted Jun 15, 2021·0 cites·18 claims
- 1462US10064963B2Methods and compositions for treating disordersPIERIS AG·Filed 2013·Granted Sep 4, 2018·1 cites·8 claims
- 1561US8475803B2Assays for diagnosis of tuberculosis and uses thereofOLWILL SHANE A·Filed 2006·Granted Jul 2, 2013·3 cites·20 claims
- 1660US2020148733A1Novel interleukin-17a-specific and interleukin-23-specific binding polypeptides and uses thereofPIERIS PHARMACEUTICALS GMBH·Filed 2019·Application pending·0 cites
- 1759US2021198380A1Anti-cancer fusion polypeptidePIERIS PHARMACEUTICALS GMBH·Filed 2020·Application pending·0 cites
- 1856US2017066807A1Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3PIERIS PHARMACEUTICALS GMBH·Filed 2016·Application pending·0 cites
- 1951US2024166763A1Her2/4-1bb bispecific fusion proteins for the treatment of cancerPIERIS PHARMACEUTICALS GMBH·Filed 2020·Application pending·0 cites
- 2051US2024166764A1Her2/4-1bb bispecific fusion proteins for the treatment of cancerPIERIS PHARMACEUTICALS GMBH·Filed 2022·Application pending·0 cites
- 2150US2023227568A1Multimeric immunomodulator targeting 4-1bbPIERIS PHARMACEUTICALS GMBH·Filed 2021·Application pending·0 cites
- 2247US8846868B2Anti-AREG/HB-EGF antibodies and treatmentCASWELL JILL·Filed 2009·Granted Sep 30, 2014·0 cites·11 claims
- 2347US2021363257A1Novel fusion protein specific for cd137 and pd-l1PIERIS PHARMACEUTICALS GMBH·Filed 2019·Application pending·0 cites
- 2446US2021246219A1Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereofPIERIS PHARMACEUTICALS GMBH·Filed 2019·Application pending·0 cites
- 2545US12486330B2Fusion proteins specific for CD137 and GPC3PIERIS PHARMACEUTICALS GMBH·Filed 2020·Granted Dec 2, 2025·0 cites·6 claims
- 2643US8747849B2Antibody and uses thereofSCOTT CHRISTOPHER·Filed 2011·Granted Jun 10, 2014·0 cites·10 claims
- 2743US7939642B2Antibody and uses thereofFUSION ANTIBODIES LTD·Filed 2006·Granted May 10, 2011·0 cites·9 claims
- 2840US2011020404A1Diagnostic method and kitFUSION ANTIBODIES LTD·Filed 2008·Application pending·0 cites
- 2937US9321838B2Therapy targeting cathepsin SOLWILL SHANE·Filed 2007·Granted Apr 26, 2016·0 cites·5 claims
- 3037US2010086551A1Antibody and uses thereofFUSION ANTIBODIES LTD·Filed 2007·Application pending·0 cites
- 3137US2010111965A1Combination therapyFUSION ANTIBODIES LTD·Filed 2007·Application pending·0 cites
- 3236US2019010231A1Novel fusion polypeptide specific for lag-3 and pd-1PIERIS PHARMACEUTICALS GMBH·Filed 2016·Application pending·0 cites
- 3335US10703810B2Fusion polypeptides which bind vascular endothelial growth factor a (VEGF-A) and angiopoietin-2 (Ang-2)PIERIS AUSTRALIA PTY LTD·Filed 2016·Granted Jul 7, 2020·0 cites·19 claims
Join the waitlist — get patent alerts
Get an alert when Shane Olwill files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →